Novartis, one of the world’s largest pharmaceutical companies, has executed an agreement to sell one of Sandoz Turkey’s manufacturing facilities in Gebze to Generica İlaç, a Turkish company engaged in the manufacturing, marketing and sale of pharmaceutical products since 2007. The transaction includes the transfer of all associated assets and employees of Sandoz Turkey on the Gebze site. The deal is expected to close by mid-2020 subject to obtaining the necessary approvals from regulatory authorities, including the Competition Board, the Gebze Plastic Manufacturers Organized Industrial Zone and the Ministry of Industry and Technology. After closing, Generica İlaç will continue to manufacture and supply certain products to Novartis.
Paksoy is pleased to announce that Elvan Aziz (partner), Nazlı Bezirci (counsel) and Gözde Zorlu (associate) are advising Novartis on this transaction.
Share
Related persons
You can contact us for detailed information.


Legal Information
This briefing is for information purposes; it is not legal advice. If you have questions, please call us. All rights reserved.
You May Be Interested In
16 February 2026
Paksoy advised H.I.G. Capital on its acquisition of Atlas Dunnage
Paksoy advised H.I.G. Capital on its acquisition of Atlas Dunnage.
12 February 2026
Paksoy advised Tiryaki Agro on its acquisition of Savola Foods Turkey
Paksoy advised Tiryaki Agro on its acquisition of Savola Foods Turkey.
19 January 2026
Paksoy advises Amphenol on its acquisition of CommScope’s CCS business
Paksoy advises Amphenol Corporation on its acquisition of CommScope’s Connectivity and Cable Solutions (CCS) business.
14 January 2026
Paksoy advised Stellantis Group on the sale of BPF Pazarlama to TOFAŞ
Paksoy advised Stellantis Group on the sale of BPF Pazarlama to TOFAŞ.
13 January 2026
Paksoy advised IFC on its investment in Getmobil
Paksoy advised IFC on its investment in Getmobil.
12 January 2026
Mergermarket has ranked us #1 Legal Adviser in Turkey by deal value for 2025
Mergermarket has ranked us #1 Legal Adviser in Turkey by deal value for 2025, advising on USD 4.97 billion across 18 transactions.